Shots:

• Foghorn will receive an upfront- development- regulatory and commercial milestones totaling up to $425M as well as royalties on sales of any approved therapy emerges from the collaboration
• Merck to get an exclusive global right to develop and commercialize drugs targeting dysregulation of a single transcription factor. The collaboration will deploy Foghorn’s Gene Traffic Control platform to discover and develop novel therapies against a transcription factor target
• Utilizing its Gene Traffic Control platform- Foghorn is interrogating and drugging the chromatin regulatory system. The company is advancing ~10 small molecule and protein degrader programs across multiple cancer indications and expects to file an IND for its first program in H2’20

Click here to read full press release/ article 

Ref: PRNewswire | Image: Merck